The success of IVF hinges on “which embryo is transferred first”—What differences in implantation probability, undetectable by visual inspection, did AI learn from 8M embryo images and prognosis data?

This podcast episode offers two distinct analyses within the healthcare sector: one focusing on reproductive medicine AI and the other on pharmaceutical sales strategy in cardiology. The first section details how the company Medeta is utilizing AI, trained on millions of embryo images and outcome data, to non-invasively select embryos with higher implantation and lower miscarriage rates for in vitro fertilization (IVF), aiming to improve success rates beyond traditional visual grading methods. The second major topic examines Novartis’s shift in its cardiovascular sales approach, prioritizing "improving the medical environment and solving healthcare issues" over simple product promotion, specifically targeting the low LDL cholesterol management rate in Japan by restructuring the role and metrics of its medical representatives (MRs) to facilitate a regional care pathway for drugs like the PCSK9 inhibitor Leqvio.